Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
暂无分享,去创建一个
[1] W. Greco,et al. The search for synergy: a critical review from a response surface perspective. , 1995, Pharmacological reviews.
[2] R Dawson,et al. Mechanism of sodium nitroprusside-mediated inhibition of aromatic amino acid decarboxylase activity. , 1995, Pharmacology.
[3] Ronald J. Tallarida,et al. Statistical analysis of drug combinations for synergism , 1992, Pain.
[4] R. E. Durand,et al. Cisplatin and CCNU synergism in spheroid cell subpopulations. , 1990, British Journal of Cancer.
[5] Arnold J Levine,et al. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas. , 2002, Genes & development.
[6] P Posner,et al. Irreversible binding of acetylethylcholine mustard to cardiac cholinergic muscarinic receptors. , 1986, Molecular pharmacology.
[7] Shu-Yun Cheng,et al. New analogues of AHMA as potential antitumor agents: synthesis and biological activity. , 2003, Bioorganic & medicinal chemistry.
[8] J. Jez,et al. Characterization of the substrate binding site in rat liver 3alpha-hydroxysteroid/dihydrodiol dehydrogenase. The roles of tryptophans in ligand binding and protein fluorescence. , 1996, The Journal of biological chemistry.
[9] D. Schoepp,et al. Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-aminopyrrolidine-2,4-dicarboxylate , 1995, Neuropharmacology.
[10] B. Zemelman,et al. Host response to Escherichia coli heat-labile enterotoxin via two microvillus membrane receptors in the rat intestine , 1989, Infection and immunity.
[11] Stanislaw M. Stepkowski,et al. SYNERGISTIC IMMUNOSUPPRESSIVE ACTIONS OF CYCLOSPORINE WITH A MOUSE ANTI‐RAT α/β‐T CELL RECEPTOR MONOCLONAL ANTIBODY , 1994 .
[12] B D Kahan,et al. Synergistic interactions of cyclosporine and rapamycin to inhibit immune performances of normal human peripheral blood lymphocytes in vitro. , 1991, Transplantation.
[13] Huiyun Liang,et al. Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells. , 2004, Molecular cancer therapeutics.
[14] Ting-Chao Chou,et al. Enhanced hydrolytic stability and water solubility of an aromatic nitrogen mustard by conjugation with molecular umbrellas. , 2003, Bioconjugate chemistry.
[15] Jang-Yang Chang,et al. Antitumor AHMA linked to DNA minor groove binding agents: synthesis and biological evaluation. , 2002, Journal of medicinal chemistry.
[16] J. Brown,et al. Antitumour activity of XR5944 in vitro and in vivo in combination with 5-fluorouracil and irinotecan in colon cancer cell lines , 2005, British Journal of Cancer.
[17] W. Bornmann,et al. Reversal of anticancer multidrug resistance by the ardeemins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[18] A. Fairlamb,et al. Characterisation of pentamidine-resistant Trypanosoma brucei brucei. , 1995, Molecular and biochemical parasitology.
[19] T. Chou,et al. Determination of availability of ligand binding site at steady state for topological assessment of receptors with the aid of microcomputers , 1990 .
[20] Dwayne D. Hegedus,et al. The Effects of Temperature on the Pathogenicity of Heat-Sensitive Mutants of the Entomopathogenic Fungus,Beauveria bassiana,toward the Migratory Grasshopper,Melanoplus sanguinipes , 1996 .
[21] A. Goldin,et al. DRUG SYNERGISM IN ANTINEOPLASTIC CHEMOTHERAPY. , 1964, Advances in chemotherapy.
[22] N. S. Loumbourdis,et al. Cadmium Accumulation in Liver and Kidneys and Hepatic Metallothionein and Glutathione Levels in Rana ridibunda, After Exposure to CdCl2 , 1998, Archives of environmental contamination and toxicology.
[23] A. Sartorelli,et al. Maintenance of retinoic acid receptor alpha pools by granulocyte colony-stimulating factor and lithium chloride in all-trans retinoic acid-treated WEHI-3B leukemia cells: relevance to the synergistic induction of terminal differentiation. , 2000, Blood.
[24] B. Steele. For More Information , 2000, Journal of the National Cancer Institute.
[25] B D Kahan,et al. Synergistic interactions of cyclosporine, rapamycin, and brequinar on heart allograft survival in mice. , 1994, Transplantation proceedings.
[26] Hubert Wiener,et al. Rabit distal colon epithelium: II. Characterization of (Na+, K+, Cl−)-cotransport and [3H]-bumetanide binding , 1989, The Journal of Membrane Biology.
[27] B. Sevin,et al. Chemosensitivity testing in gynecologic malignancies and breast cancer , 1994 .
[28] T C Chou,et al. Quantitation of chemopreventive synergism between (-)-epigallocatechin-3-gallate and curcumin in normal, premalignant and malignant human oral epithelial cells. , 1998, Carcinogenesis.
[29] B D Kahan,et al. Synergistic effect of the rapamycin-cyclosporine combination: median effect analysis of in vitro immune performances by human T lymphocytes in PHA, CD3, and MLR proliferative and cytotoxicity assays. , 1991, Transplantation proceedings.
[30] T. Chou,et al. Combined antiviral effects of paired nucleosides against guinea pig cytomegalovirus replication in vitro. , 1990, Antiviral research.
[31] A. Tsaroucha,et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings. , 1997, Transplant immunology.
[32] T. Chou,et al. Interferon-alpha and 3'-azido-3'-deoxythymidine are highly synergistic in mice and prevent viremia after acute retrovirus exposure. , 1990, Journal of acquired immune deficiency syndromes.
[33] P. Laneuville,et al. bcr/abl expression in 32D cl3(G) cells inhibits apoptosis induced by protein tyrosine kinase inhibitors. , 1994, Cancer research.
[34] T. Chou,et al. In Vitro Anti-HIV-1 Synergy between Non-Nucleoside Reverse Transcriptase Inhibitors Nevirapine and Efavirenz , 2000, Antiviral therapy.
[35] K. Savin,et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Reiffenstein,et al. Application of the isobologram technique for the analysis of combined effects with respect to additivity as well as independence. , 1990, Canadian journal of physiology and pharmacology.
[37] M. Hirsch,et al. Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro , 1992, Antimicrobial Agents and Chemotherapy.
[38] T. Chou,et al. Synergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidine , 1991, Antimicrobial Agents and Chemotherapy.
[39] T R Kelly,et al. Intercalating agents with covalent bond forming capability. A novel type of potential anticancer agents. 2. Derivatives of chrysophanol and emodin. , 1989, Journal of medicinal chemistry.
[40] S. Sacks,et al. The synergistic effects of betulin with acyclovir against herpes simplex viruses. , 2004, Antiviral research.
[41] T. Chou,et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by 3'-fluoro-3'-deoxythymidine, recombinant soluble CD4, and recombinant interferon-alpha. , 1992, AIDS research and human retroviruses.
[42] W. Cleland,et al. The kinetics of enzyme-catalyzed reactions with two or more substrates or products. II. Inhibition: nomenclature and theory. , 1963, Biochimica et biophysica acta.
[43] Jing Wang,et al. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis. , 2006, Cancer research.
[44] Cynthia Czajkowski,et al. Mapping the Agonist Binding Site of the GABAAReceptor: Evidence for a β-Strand , 1999, The Journal of Neuroscience.
[45] Joseph R. DiPalma,et al. Principles of Drug Action: The Basis of Pharmacology , 1968 .
[46] C. S. McKee. The Determination of Hydrogen Ions , 1928 .
[47] T. Chou,et al. Potent antitumor N-mustard derivatives of 9-anilinoacridine, synthesis and antitumor evaluation. , 2004, Bioorganic & medicinal chemistry letters.
[48] Y. Nakabeppu,et al. Sensitivity of Escherichia coli (MutT) and human (MTH1) 8-oxo-dGTPases to in vitro inhibition by the carcinogenic metals, nickel(II), copper(II), cobalt(II) and cadmium(II). , 1997, Carcinogenesis.
[49] M. Hirsch,et al. Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro , 1994, Antimicrobial Agents and Chemotherapy.
[50] D. Schoepp,et al. Comparison of Excitatory Amino Acid‐Stimulated Phosphoinositide Hydrolysis and N‐[3H]Acetylaspartylglutamate Binding in Rat Brain: Selective Inhibition of Phosphoinositide Hydrolysis by 2‐Amino‐3‐Phosphonopropionate , 1989, Journal of neurochemistry.
[51] C. Nordling. A New Theory on the Cancer-inducing Mechanism , 1953, British Journal of Cancer.
[52] N. Mantel,et al. The employment of combinations of drugs in the chemotherapy of neoplasia: a review. , 1957, Cancer research.
[53] P. Skehan,et al. Membrane-active drugs potentiate the killing of tumor cells by D-glucosamine. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[54] P. Ornstein,et al. Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action. , 1990, The Journal of pharmacology and experimental therapeutics.
[55] P. N. Lee,et al. Cancer and ageing in mice and men. , 1975, British Journal of Cancer.
[56] T. Chou,et al. A rigorous approach to the diagnosis of synergy among combination therapies of immunosuppressive agents , 2001 .
[57] D E Sutherland,et al. Synergistic effect of 15-deoxyspergualin and cyclosporine in prolonging survival of rat cardiac allografts. , 1994, Transplantation proceedings.
[58] G. Pasternak,et al. Sigma1 binding in a human neuroblastoma cell line , 1996, Neurochemical Research.
[59] T. Chou,et al. Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication , 1996, Antimicrobial agents and chemotherapy.
[60] P. Sexton,et al. Molecular Pharmacology , 1965, Nature.
[61] T. Chou,et al. Cell differentiation effects of 2'-fluoro-1-beta-D-arabinofuranosyl pyrimidines in HL-60 cells. , 1987, Leukemia research.
[62] F. M. Hack,et al. Modulation of intrinsic in vitro resistance to carboplatin by edatrexate in the A549 human nonsmall cell lung cancer cell line. , 1994, Oncology research.
[63] Patrick J. Hannan,et al. HT-2 toxin, roridin A, T-2 toxin, and verrucarin A mycotoxins inhibit carbon dioxide production by Kluyveromyces marxianus , 1991 .
[64] David Bom,et al. 7-Silylcamptothecins (silatecans): A new family of camptothecin antitumor agents , 1997 .
[65] M. Egorin,et al. Interaction of N,N',N''-triethylenethiophosphoramide and N,N',N''-triethylenephosphoramide with cellular DNA. , 1991, Cancer research.
[66] T. Chou,et al. Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3'-fluoro-3'-deoxythymidine and 3'-azido-3'-deoxythymidine , 1992, Antimicrobial Agents and Chemotherapy.
[67] A. Perelson,et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. , 1999, The New England journal of medicine.
[68] M. Kris,et al. Phase I study of the sequential administration of edatrexate and paclitaxel in patients with advanced solid tumors. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.
[69] R. Barrett,et al. Ligand dissociation constants from competition binding assays: errors associated with ligand depletion. , 1987, Molecular pharmacology.
[70] T. Chou,et al. Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. , 2005, European journal of biochemistry.
[71] H. Okamura,et al. Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats. , 1996, Life sciences.
[72] H. Turndorf,et al. On the mechanism of the interaction of ketamine and halothane in vitro. , 1992, General pharmacology.
[73] James F. Holland,et al. Biologic and pharmacologic effects of harringtonine on human leukemia-lymphoma cells , 2004, Cancer Chemotherapy and Pharmacology.
[74] M. Israel,et al. Effects of N-trifluoroacetyladriamycin-14-O-hemiadipate and radiation on L1210 cells. , 1986, Radiation research.
[75] B. K. Chang,et al. Schedule-dependent interaction of alpha-difluoromethylornithine and cis-diamminedichloroplatinum(II) against human and hamster pancreatic cancer cell lines. , 1987, Cancer research.
[76] T. Chou,et al. Analogues of taurine as stimulators and inhibitors of ATP-dependent calcium ion uptake in rat retina: combination kinetics. , 1989, Molecular pharmacology.
[77] Erik J. Sorensen,et al. Remote Effects in Macrolide Formation Through Ring-Forming Olefin Metathesis: An Application to the Synthesis of Fully Active Epothilone Congeners. , 1997 .
[78] C. I. Bliss. THE TOXICITY OF POISONS APPLIED JOINTLY1 , 1939 .
[79] D. Richman,et al. In vitro Anti-HIV-1 Activity of sn-2-Substituted 1-O-Octadecyl-sn-Glycero-3-Phosphonoformate Analogues and Synergy with Zidovudine , 2000, Antiviral chemistry & chemotherapy.
[80] N Mantel,et al. Evaluation of combination chemotherapy with three drugs. , 1968, Cancer research.
[81] Amy Zuckerman,et al. Pharmacological characterization of morphine-6-sulfate and codeine-6-sulfate , 1999, Brain Research.
[82] W R Greco,et al. Application of a new approach for the quantitation of drug synergism to the combination of cis-diamminedichloroplatinum and 1-beta-D-arabinofuranosylcytosine. , 1990, Cancer research.
[83] Leslie Wilson,et al. Synergistic Suppression of Microtubule Dynamics by Discodermolide and Paclitaxel in Non-Small Cell Lung Carcinoma Cells , 2004, Cancer Research.
[84] B. Smith,et al. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. , 2004, Blood.
[85] M. Dowsett,et al. Biochemistry and pharmacokinetics of potent non-steroidal cytochrome P45017α inhibitors , 1997, The Journal of Steroid Biochemistry and Molecular Biology.
[86] N. Magné,et al. Dual HER 1-2 targeting of hormone-refractory prostate cancer by ZD1839 and trastuzumab. , 2004, European journal of cancer.
[87] M Price,et al. Receptor binding of [3H]naloxone benzoylhydrazone: a reversible kappa and slowly dissociable mu opiate. , 1989, Molecular pharmacology.
[88] Susan Band Horwitz,et al. Structure–Activity Relationship of the Epothilones and the First In Vivo Comparison with Paclitaxel† , 1997 .
[89] G. Pasternak,et al. Kappa opiate receptor multiplicity: evidence for two U50,488-sensitive kappa 1 subtypes and a novel kappa 3 subtype. , 1989, The Journal of pharmacology and experimental therapeutics.
[90] T. Chou,et al. Comparison of the mass action law with the power law the probit law and the logit law in dose effect analyses , 1977 .
[91] Ivana Vucenik,et al. Anti-angiogenic activity of inositol hexaphosphate (IP6). , 2004, Carcinogenesis.
[92] Beverly S Mitchell,et al. Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. , 2005, Blood.
[93] T. Chou,et al. Uptake, initial effects, and chemotherapeutic efficacy of harringtonine in murine leukemic cells sensitive and resistant to vincristine and other chemotherapeutic agents. , 1983, Cancer research.
[94] Roger M Macklis,et al. Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines. , 2005, International Journal of Radiation Oncology, Biology, Physics.
[95] T. Chou,et al. On the total synthesis and preliminary biological evaluations of 15(R) and 15(S) aza-dEpoB: a Mitsunobu inversion at C15 in pre-epothilone fragments. , 2000, Organic letters.
[96] A Gebre-Hiwot,et al. The in-vitro anti-leishmanial activity of inhibitors of ergosterol biosynthesis. , 1993, The Journal of antimicrobial chemotherapy.
[97] M. Hirsch,et al. Lamivudine or stavudine in two- and three-drug combinations against human immunodeficiency virus type 1 replication in vitro. , 1996, The Journal of infectious diseases.
[98] Christof M. Kramm,et al. Temozolomide enhances herpes simplex virus thymidine kinase/ganciclovir therapy of malignant glioma , 2001, Cancer Gene Therapy.
[99] T. Yorio,et al. Characterization of alpha 2-adrenoceptor binding sites in rabbit ciliary body membranes. , 1994, Investigative ophthalmology & visual science.
[100] Joseph Ciccolini,et al. Taxotere–5′-deoxy-5-fluorouridine combination on hormone-refractory human prostate cancer cells , 2005, Anti-cancer drugs.
[101] J. Merlin,et al. In vitro evaluation of Taxol combined with radiations in human squamous cell carcinoma spheroids. , 1996, Cancer letters.
[102] X. Kong,et al. Preclinical Pharmacology and Pharmacokinetics of the Anti-Hepatitis Virus Agent 2'-Fluoro-5-Ethyl-1-β-D-Arabinofuranosyluracil in Mice and Rats , 1992, Antimicrobial Agents and Chemotherapy.
[103] T. Chou,et al. Synthesis of the acridone alkaloids glyfoline and congeners. Structure-activity relationship studies of cytotoxic acridones. , 1992, Journal of medicinal chemistry.
[104] T. Chou,et al. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.
[105] T. Chou,et al. Assessment of synergistic and antagonistic effects of chemotherapeutic agents in vitro. , 1994, Contributions to gynecology and obstetrics.
[106] T. Chou,et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. , 1997, Transplantation proceedings.
[107] Hong Lu,et al. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. , 2005, Immunobiology.
[108] W. Lamph,et al. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma , 2004, Breast Cancer Research and Treatment.
[109] J. Woodward,et al. The putative polyamine antagonists ifenprodil and SL 82.0715 enhance dopamine efflux from rat striatal slices independent of NMDA receptor activation. , 1992, European journal of pharmacology.
[110] Chou Ting-Chao Chou,et al. Conservation of laboratory animals by improved experimental design, generalized equations and computer analysis , 1984 .
[111] D. Burk,et al. The Determination of Enzyme Dissociation Constants , 1934 .
[112] D. Schoepp,et al. The Novel Metabotropic Glutamate Receptor Agonist 2R,4R-APDC Potentiates Stimulation of Phosphoinositide Hydrolysis in the Rat Hippocampus by 3,5-dihydroxyphenylglycine: Evidence for a Synergistic Interaction Between Group 1 and Group 2 Receptors , 1996, Neuropharmacology.
[113] Martin S. Hirsch,et al. Strong in Vitro Synergy Between the Fusion Inhibitor T‐20 and the CXCR4 Blocker AMD‐3100 , 2000, Journal of acquired immune deficiency syndromes.
[114] Chien-Fu Lin,et al. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel , 2006, Cancer Chemotherapy and Pharmacology.
[115] Eric Cundliffe,et al. Protein synthesis inhibitors , 1979, Nature.
[116] Bangaru Chandrasekaran,et al. Synchronization of cells in the S phase of the cell cycle by 3′-azido-3′-deoxythymidine: implications for cell cytotoxicity , 2004, Cancer Chemotherapy and Pharmacology.
[117] B D Kahan,et al. THE IMMUNOSUPPRESSIVE ANTAGONISM OF LOW DOSES OF FK506 AND CYCLOSPORINE , 1991, Transplantation.
[118] T C Chou,et al. Biochemical effects of 2'-fluoro-5-methyl-1-beta-D-arabinofuranosyluracil and 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in mouse leukemic cells sensitive and resistant to 1-beta-D-arabinofuranosylcytosine. , 1982, Cancer research.
[119] J M Moerschbaecher,et al. A phencyclidine recognition site is associated with N-methyl-D-aspartate inhibition of carbachol-stimulated phosphoinositide hydrolysis in rat cortical slices. , 1989, Molecular pharmacology.
[120] E. Vaughan,et al. An in vivo evaluation of alpha adrenergic receptors in canine prostate. , 1989, The Journal of urology.
[121] T. Chou,et al. Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2- fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta. , 1990, Antiviral research.
[122] T. Chou,et al. Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. , 1999, Cancer research.
[123] Susan Zolla-Pazner,et al. Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins , 1998, Journal of Virology.
[124] T. Chou,et al. Cyclopent[a]anthraquinones as DNA intercalating agents with covalent bond formation potential: synthesis and biological activity. , 1996, Journal of medicinal chemistry.
[125] B D Kahan,et al. Beneficial effect of graft perfusion with anti-T cell receptor monoclonal antibodies on survival of small bowel allografts in rat recipients treated with brequinar alone or in combination with cyclosporine and sirolimus. , 1996, Transplantation.
[126] T. Chou,et al. Synergism and antagonism in chemotherapy , 1991 .
[127] T C Chou,et al. Synergistic interaction of 15-deoxyspergualin and cyclosporine to prolong the survival of rat islet allografts. , 1994, Transplantation proceedings.
[128] M Naguib,et al. Neuromuscular Effects of Rocuronium Bromide and Mivacurium Chloride Administered Alone and in Combination , 1994, Anesthesiology.
[129] P. Molinoff,et al. Thermodynamic differences between agonist and antagonist interactions with binding sites for [3H]spiroperidol in rat striatum. , 1983, Molecular pharmacology.
[130] T B Johnson,et al. The enhancement of the activity of 10-propargyl-5,8-dideazafolate and 5,10-dideazatetrahydrofolate by inhibitors of dihydrofolate reductase. , 1989, Advances in enzyme regulation.
[131] L. Lennard,et al. Principles of Drug Action. The Basis of Pharmacology , 1991 .
[132] Colin Sumners,et al. Irreversible Binding and Recovery of the Norepinephrine Uptake System Using an Alkylating Derivative of Norepinephrine , 1988, Journal of neurochemistry.
[133] G. Wahlström,et al. Interactions between hexobarbital and thiopental in male rats evaluated with an anaesthesia threshold. , 2009, Acta pharmacologica et toxicologica.
[134] P. Colombani,et al. Drug-drug interaction between cyclosporine and agents affecting calcium-dependent lymphocyte proliferation. , 1989, Transplantation proceedings.
[135] Carsten Müller-Tidow,et al. Synergistic growth inhibitory effects of interferon-alpha and lovastatin on bcr-abl positive leukemic cells. , 2003, International journal of oncology.
[136] F. M. Hack,et al. Schedule-dependent synergism of edatrexate and cisplatin in combination in the A549 lung-cancer cell line as assessed by median-effect analysis , 2004, Cancer Chemotherapy and Pharmacology.
[137] T. Chou,et al. Synthesis of 4-[(1,3-diaminopyrrolo[3′,4′:4,5]pyrido[2,3-d]-pyrimidin-8-yl)benzoyl]-L-glutamic acid as a potential antifolate , 1993 .
[138] Nordling Co. A New Theory on the Cancer-inducing Mechanism , 1953 .
[139] Berenbaum Mc. What is synergy? , 1989, Pharmacological reviews.
[140] A. Hill,et al. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves , 1910 .
[141] T. Chou,et al. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles1 , 1996 .
[142] T. Chou,et al. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains. , 1996, AIDS research and human retroviruses.
[143] T. Chou,et al. Overview: DNA Topoisomerase Targeted Anticancer Agents: New Trends and Developments , 1992 .
[144] M. Hirsch,et al. Synergistic cytotoxic effect of azidothymidine and recombinant interferon alpha on normal human bone marrow progenitor cells. , 1989, Blood.
[145] D. Richman,et al. BI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudine , 1991, Antimicrobial Agents and Chemotherapy.
[146] Tahir A. Rizvi,et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection , 2000, Nature Medicine.
[147] H. Skipper,et al. Combination therapy: some concepts and results. , 1974, Cancer chemotherapy reports. Part 2.
[148] D R Burton,et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. , 2001, Journal of human virology.
[149] M. Puig,et al. Synergistic Interaction of Morphine and Halothane in the Guinea Pig Ileum , 1988, Anesthesiology.
[150] F. Meyskens,et al. Difluoromethylornithine enhances inhibition of melanoma cell growth in soft agar by dexamethasone, clone a interferon and retinoic acid , 1986, International journal of cancer.
[151] E. Michelotti,et al. Antifungal properties of taxol and various analogues , 1992, Experientia.
[152] J. Lewis,et al. Probit Analysis (3rd ed). , 1972 .
[153] H. Abou-Issa,et al. Combined effects of interferon and steroid hormones on 2',5'-oligoadenylate synthetase activity in chronic lymphocytic leukemia cells. , 1989, Leukemia research.
[154] B D Kahan,et al. Prospects for synergistic immunosuppressive drug therapy in the coming decade. , 1992, Transplantation proceedings.
[155] R. Motzer,et al. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.
[156] G. Klein,et al. Comparative quantitative electrophysiologic effects of adenosine triphosphate on the sinus node and atrioventricular node. , 1988, The American journal of cardiology.
[157] Jindrich Cinatl,et al. Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines , 2004, Biochemical and Biophysical Research Communications.
[158] C Pettinelli,et al. Methodological issues in AIDS clinical trials. Application of the combination index method in the design of a clinical antiretroviral trial: ACTG 068. , 1990, Journal of acquired immune deficiency syndromes.
[159] R F Schinazi,et al. Delayed treatment with combinations of antiviral drugs in mice infected with herpes simplex virus and application of the median effect method of analysis , 1986, Antimicrobial Agents and Chemotherapy.
[160] Joseph Berkson,et al. Approximation of Chi-Square by “Probits” and by “Logits” , 1946 .
[161] C. Calatozzolo,et al. Effect of association of temozolomide with other chemotherapic agents on cell growth inhibition in glioma cell lines. , 2004, Oncology research.
[162] F. Guillemin,et al. Parameters Affecting Photodynamic Activity of Foscan® or Meta-tetra(hydroxyphenyl)chlorin (mTHPC) In Vitro and In Vivo , 1998, Lasers in Medical Science.
[163] J B Smith,et al. Lowering extracellular pH evokes inositol polyphosphate formation and calcium mobilization. , 1989, The Journal of biological chemistry.
[164] Tomas Radivoyevitch,et al. The interaction between two radiosensitizers: 5-iododeoxyuridine and caffeine. , 2006, Cancer research.
[165] M. Hirsch,et al. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between protease inhibitor Ro 31-8959 and zidovudine, 2',3'-dideoxycytidine, or recombinant interferon-alpha A against zidovudine-sensitive or -resistant HIV-1 in vitro. , 1992, The Journal of infectious diseases.
[166] A. Kremer,et al. The active site of transketolase. Two arginine residues are essential for activity. , 1980, The Journal of biological chemistry.
[167] Skipper He,et al. Combination therapy: some concepts and results. , 1974 .
[168] Ting-Chao Chou,et al. Synthesis of cyclopentanthraquinones: analogs of mitomycin C , 1993 .
[169] B D Kahan,et al. Analysis of the interactions of immunosuppressive drugs with cyclosporine in inhibiting DNA proliferation. , 1990, Transplantation.
[170] R. A. Gonzales,et al. Alcohol-induced inhibition of N-methyl-d-aspartate-evoked release of [3H]norepinephrine from brain is related to lipophilicity , 1991, Neuropharmacology.
[171] S H Chu,et al. Age and cortisone alter host responsiveness to cholera toxin in the developing gut. , 1989, The American journal of physiology.
[172] R. Schooley,et al. Synergistic inhibition of human T-cell lymphotropic virus type III replication in vitro by phosphonoformate and recombinant alpha-A interferon , 1986, Antimicrobial Agents and Chemotherapy.
[173] B. Clarkson,et al. Comparative cytotoxicity of various drug combinations for human leukemic cells and normal hematopoietic precursors. , 1987, Cancer research.
[174] J J Mooney,et al. Neuronal monoamine reuptake inhibitors enhance in vitro susceptibility to chloroquine in resistant Plasmodium falciparum , 1994, Antimicrobial Agents and Chemotherapy.
[175] T. Chou,et al. Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro , 2004, Cancer Chemotherapy and Pharmacology.
[176] Roy E. Byington,et al. Two drug combinations of zidovudine, didanosine, and recombinant interferon-alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. , 1991, Disease markers.
[177] J H Goldie,et al. Interaction of etoposide and cisplatin in an in vitro tumor model. , 1987, Cancer treatment reports.
[178] R. Howells,et al. ADVANCES IN CHEMOTHERAPHY , 1982 .
[179] F. Sharom,et al. Linear and cyclic peptides as substrates and modulators of P-glycoprotein: peptide binding and effects on drug transport and accumulation. , 1998, The Biochemical journal.
[180] J. Woodward,et al. Ethanol Inhibition of N‐Methyl‐D‐Aspartate‐Stimulated Endogenous Dopamine Release from Rat Striatal Slices: Reversal by Glycine , 1990, Journal of neurochemistry.
[181] A C UPTON,et al. The dose-response relation in radiation-induced cancer. , 1961, Cancer research.
[182] F. Lo‐Coco,et al. Arsenic trioxide (ATO) and MEK1 inhibition synergize to induce apoptosis in acute promyelocytic leukemia cells , 2005, Leukemia.
[183] B D Kahan,et al. Pharmacokinetic interactions augment toxicities of sirolimus/cyclosporine combinations. , 2001, Journal of the American Society of Nephrology : JASN.
[184] T. Chou,et al. Topoisomerase II-mediated DNA cleavage activity and irreversibility of cleavable complex formation induced by DNA intercalator with alkylating capability. , 1992, Molecular pharmacology.
[185] R. Schooley,et al. Synergistic interaction of 2',3'-dideoxycytidine and recombinant interferon-alpha-A on replication of human immunodeficiency virus type 1. , 1988, The Journal of infectious diseases.
[186] T C Chou,et al. Synthesis and structure-activity relationships of potential anticancer agents: alkylcarbamates of 3-(9-acridinylamino)-5-hydroxymethylaniline. , 1999, Journal of medicinal chemistry.
[187] R Vertua,et al. Effects of divalent cations on adenosine agonist binding to A1 receptors and non-A1/non-A2 sites in rat cerebral cortex. , 1994, Pharmacology & toxicology.
[188] A. Donson,et al. Tamoxifen radiosensitization in human glioblastoma cell lines. , 1999, Journal of neurosurgery.
[189] Jing Chen,et al. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. , 2005, Blood.
[190] Ann Collier,et al. Combination and Monotherapy with Zidovudine and Zalcitabine in Patients with Advanced HIV Disease , 1995, Annals of Internal Medicine.
[191] Ting-Chao Chou. Chemotherapy: Synergism and Antagonism , 2002 .
[192] R Peto,et al. Editorial: Guidelines on the analysis of tumour rates and death rates in experimental animals. , 1974, British Journal of Cancer.
[193] T. Chou,et al. Combinatorial analysis of multiple substrate-multiple product enzyme reactions. , 1972, Journal of theoretical biology.
[194] Walter Jaeger,et al. Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. , 2005, Experimental hematology.
[195] J. Gaddum. Probit Analysis , 1948, Nature.
[196] C. Schultz,et al. Cyclic AMP stimulates the cyclic GMP egression pump in human erythrocytes: effects of probenecid, verapamil, progesterone, theophylline, IBMX, forskolin, and cyclic AMP on cyclic GMP uptake and association to inside-out vesicles. , 1998, Biochemistry.
[197] F. Fonnum,et al. Comparison of the Properties of γ‐Aminobutyric Acid and L‐Glutamate Uptake into Synaptic Vesicles Isolated from Rat Brain , 1989, Journal of neurochemistry.
[198] B D Kahan,et al. The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination. , 1993, Transplantation.
[199] J. Bertino,et al. Pretreatment of colon carcinoma cells with Tomudex enhances 5-fluorouracil cytotoxicity. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[200] Susan Band Horwitz,et al. Total Synthesis of (–)‐Epothilone B: An Extension of the Suzuki Coupling Method and Insights into Structure–Activity Relationships of the Epothilones , 1997 .
[201] W. Stone,et al. Evidence for a possible functional interaction between serotonergic and cholinergic mechanisms in memory retrieval. , 1987, Behavioral and neural biology.
[202] D. Schoepp,et al. LY354740 is a Potent and Highly Selective Group II Metabotropic Glutamate Receptor Agonist in Cells Expressing Human Glutamate Receptors , 1997, Neuropharmacology.
[203] P Palatini,et al. Canrenone as a partial agonist at the digitalis receptor site of sodium-potassium-activated adenosine triphosphatase. , 1981, The Journal of pharmacology and experimental therapeutics.
[204] W. Walker,et al. Development of Intestinal Host Defense: An Increased Sensitivity in the Adenylate Cyclase Response to Cholera Toxin in Suckling Rats , 1989, Pediatric Research.
[205] Goldie Jh,et al. Interaction of etoposide and cisplatin in an in vitro tumor model. , 1987 .
[206] W. R. Thompson,et al. USE OF MOVING AVERAGES AND INTERPOLATION TO ESTIMATE MEDIAN-EFFECTIVE DOSE: I. Fundamental Formulas, Estimation of Error, and Relation to Other Methods. , 1947, Bacteriological reviews.
[207] B. Koehler,et al. Synthesis of Cyclopentanthraquinones: Analogues of Mitomycin C. , 1993 .
[208] Yun Dai,et al. The small-molecule Bcl-2 inhibitor HA14-1 interacts synergistically with flavopiridol to induce mitochondrial injury and apoptosis in human myeloma cells through a free radical-dependent and Jun NH2-terminal kinase-dependent mechanism. , 2004, Molecular cancer therapeutics.
[209] R. Schooley,et al. Synergistic inhibition of human immunodeficiency virus in vitro by azidothymidine and recombinant alpha A interferon , 1987, Antimicrobial Agents and Chemotherapy.
[210] A. Brill,et al. Leukemia in Hiroshima atomic bomb survivors. , 1960, Blood.
[211] J. Woodward,et al. Redox Modulation of N‐Methyl‐D‐Aspartate‐Stimulated Neurotransmitter Release from Rat Brain Slices , 1991, Journal of neurochemistry.
[212] P. Armitage,et al. The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis , 1954, British Journal of Cancer.
[213] D. Bylund,et al. Alpha-2A and alpha-2B adrenergic receptor subtypes: attenuation of cyclic AMP production in cell lines containing only one receptor subtype. , 1989, The Journal of pharmacology and experimental therapeutics.
[214] Taeyoung Yoon,et al. The Total Synthesis of Dynemicin A Leading to Development of a Fully Contained Bioreductively Activated Enediyne Prodrug , 1996 .
[215] T R Fraser,et al. Lecture on the Antagonism between the Actions of Active Substances , 1872, British medical journal.
[216] M. Clynes,et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). , 1998, European journal of cancer.
[217] Bryan R. G. Williams,et al. Synergistic Activation of Innate Immunity by Double-Stranded RNA and CpG DNA Promotes Enhanced Antitumor Activity , 2004, Cancer Research.
[218] J. Ashford. General models for the joint action of mixtures of drugs. , 1981, Biometrics.
[219] G. Scatchard,et al. THE ATTRACTIONS OF PROTEINS FOR SMALL MOLECULES AND IONS , 1949 .
[220] F. Fonnum,et al. Uptake of Glycine into Synaptic Vesicles Isolated from Rat Spinal Cord , 1990, Journal of neurochemistry.
[221] Lu Zhang,et al. The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584 , 2004, Cancer Research.
[222] Hermann Katinger,et al. Passive immunization against oral AIDS virus transmission: An approach to prevent mother‐to‐infant HIV‐1 transmission? , 2001, Journal of medical primatology.
[223] G Milano,et al. Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors , 2005, British Journal of Cancer.
[224] Yuman Fong,et al. Herpes simplex virus based gene therapy enhances the efficacy of mitomycin C for the treatment of human bladder transitional cell carcinoma. , 2004, The Journal of urology.
[225] R. Dulbecco. Encyclopedia of human biology , 1991 .
[226] J J Woodward,et al. Effects of the putative polyamine antagonists diethylenetriamine and 1,10-diaminodecane on N-methyl-D-aspartic acid-stimulated [3H]norepinephrine release from rat hippocampal slices. , 1993, The Journal of pharmacology and experimental therapeutics.
[227] G. Pasternak,et al. Demonstration of κ3‐Opioid Receptors in the SH‐SY5Y Human Neuroblastoma Cell Line , 1995 .
[228] M. Hirsch,et al. Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. , 1990, The Journal of infectious diseases.
[229] W. Cleland,et al. Enzyme kinetics revisited: a commentary on 'The Kinetics of Enzyme-Catalyzed Reactions With Two or More Substrates or Products'. , 1989, Biochimica et Biophysica Acta.
[230] D. Buchsbaum,et al. Combination of cytosine deaminase suicide gene expression with DR5 antibody treatment increases cancer cell cytotoxicity , 2006, Cancer Gene Therapy.
[231] T. Chou,et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[232] K. Maeyama,et al. The Disposition of (R)‐α‐Methylhistamine, a Histamine H3‐Receptor Agonist, in Rats , 1994 .
[233] J. Bolard,et al. Antifungal agents useful in therapy of systemic fungal infections. , 1983, Annual review of pharmacology and toxicology.
[234] J. Jaén,et al. Selective, covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multidrug-resistant tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[235] María Inés Picollo,et al. INDEPENDENT AND JOINT ACTION OF CIS- AND TRANS-PERMETHRIN IN TRIATOMA INFESTANS (HEMIPTERA: REDUVIIDAE) , 1998 .
[236] J H J Martin,et al. Synergistic antitumour effect of a combination of toremifene and interferon-alpha on ZR-75-1 human breast cancer cells: dependence on interferon-alpha subtype. , 2002, Oncology reports.
[237] Prasad Adusumilli,et al. Up‐regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a γ134.5 deleted oncolytic herpes virus (G207) , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[238] T. Chou,et al. Synergistic effect of 4-hydroperoxycyclophosphamide and etoposide on a human promyelocytic leukemia cell line (HL-60) demonstrated by computer analysis. , 1985, Cancer research.
[239] Martin S. Hirsch,et al. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. , 1999, Journal of acquired immune deficiency syndromes.
[240] T C Chou,et al. Drug combinations: From laboratory to practice , 1998 .
[241] L. M. Ballas,et al. Staurosporine and ent-Staurosporine: The First Total Syntheses, Prospects for a Regioselective Approach, and Activity Profiles. , 1996 .
[242] Abraham Weizman,et al. Interactions between laudanosine, GABA, and opioid subtype receptors: implication for laudanosine seizure activity , 1994, Brain Research.
[243] T. Chou,et al. On the determination of availability of ligand binding sites in steady-state systems. , 1977, Journal of theoretical biology.
[244] M. Baba,et al. Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha. , 2004, Antiviral research.
[245] D. Schoepp,et al. 3,5‐Dihydroxyphenylglycine Is a Highly Selective Agonist for Phosphoinositide‐Linked Metabotropic Glutamate Receptors in the Rat Hippocampus , 1994, Journal of neurochemistry.
[246] A. Hill. The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I. , 1913, The Biochemical journal.
[247] M. Netea,et al. Design of efficacy trials of cytokines in combination with antifungal drugs. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[248] M. Rowlands,et al. Inhibition of 17α-hydroxylase/C17-C20 lyase by bifluranol and its analogues , 1989 .
[249] S. Loewe,et al. Die quantitativen Probleme der Pharmakologie , 1928 .
[250] Paul Richardson,et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. , 2004, Blood.
[251] T. Chou,et al. Antagonistic interactions of hexamethylene bisacetamide in combination with 1-beta-D-arabinofuranosylcytosine, adriamycin and harringtonine on the growth and differentiation of HL-60 cells in vitro. , 1988, Leukemia research.
[252] Paul Talalay,et al. Analysis of combined drug effects: a new look at a very old problem , 1983 .
[253] R. Moran,et al. Chapter 5 – Approaches to the Rational Combination of Antimetabolites for Cancer Chemotherapy , 1975 .
[254] Susan Band Horwitz,et al. Stereoselective syntheses and evaluation of compounds in the 8-desmethylepothilone a series: Some surprising observations regarding their chemical and biological properties , 1997 .
[255] T. Chou,et al. Design of antineoplastic agents on the basis of the “2‐phenyl‐naphthalene‐type” structural pattern. 3. synthesis and biological activity evaluation of 5H‐benzo[b]naphtho‐[2,3‐d]pyrrole‐6,11‐dione derivatives , 1996 .
[256] Ursula Creutzig,et al. The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. , 2004, International journal of oncology.
[257] M C Berenbaum,et al. Criteria for analyzing interactions between biologically active agents. , 1981, Advances in cancer research.
[258] E. Vaughan,et al. Medical management of benign prostatic hyperplasia: a canine model comparing the in vivo efficacy of alpha-1 adrenergic antagonists in the prostate. , 1993, The Journal of urology.
[259] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[260] C O NORDLING. Evidence regarding the multiple mutation theory of the cancer-inducing mechanism. , 1955, Acta genetica et statistica medica.
[261] Y. Kimura,et al. Pharmacological studies on the novel antiallergic drug HQL-79: I. Antiallergic and antiasthmatic effects in various experimental models. , 1998, Japanese journal of pharmacology.
[262] T Chou,et al. Relationships between inhibition constants and fractional inhibition in enzyme-catalyzed reactions with different numbers of reactants, different reaction mechanisms, and different types and mechanisms of inhibition. , 1974, Molecular pharmacology.
[263] X. Breakefield,et al. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. , 1999, Cancer research.
[264] T. Chou,et al. Total synthesis and antitumor activity of 12,13-desoxyepothilone F: an unexpected solvolysis problem at C15, mediated by remote substitution at C21. , 2000, The Journal of organic chemistry.
[265] Albert Heim,et al. Cultured human myocardial fibroblasts of pediatric origin: Natural human interferon-α is more effective than recombinant interferon-α 2a in carrier-state coxsackievirus B3 replication , 1995 .
[266] T. Chou,et al. Synthesis and biological effects of 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil , 1987, Antimicrobial Agents and Chemotherapy.
[267] A. Murray,et al. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. , 2005, Vaccine.
[268] H VELDSTRA,et al. Synergism and potentiation with special reference to the combination of structural analogues. , 1956, Pharmacological reviews.
[269] C. Korch,et al. Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma , 2005, British Journal of Cancer.
[270] T. Chou,et al. Kinetic properties and inhibition of Acinetobacter glutaminase-asparaginase. , 1983, Biochemical pharmacology.
[271] T. Chou,et al. Preclinical pharmacology and pharmacokinetics of the anti-hepatitis virus agent 2'-fluoro-5-ethyl-1-beta-D-arabinofuranosyluracil in mice and rats , 1992, Antimicrobial Agents and Chemotherapy.
[272] Alexey Rivkin,et al. On the remarkable antitumor properties of fludelone: how we got there. , 2005, Angewandte Chemie.
[273] K Magyar,et al. Critical evaluation of the in vivo selectivity between hypotensive and platelet antiaggregating actions of iloprost and prostacyclin in beagle dogs. , 1989, Archives internationales de pharmacodynamie et de therapie.
[274] M. Heinrich,et al. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells. , 2004, Blood.
[275] Robert A. Rasmussen,et al. Postnatal Passive Immunization of Neonatal Macaques with a Triple Combination of Human Monoclonal Antibodies against Oral Simian-Human Immunodeficiency Virus Challenge , 2001, Journal of Virology.
[276] R Rode,et al. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. , 1999, AIDS.
[277] T. Chou,et al. Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine and recombinant human beta interferon alone and in combination on simian varicella virus infection in monkeys. , 1987, The Journal of infectious diseases.
[278] R. Schooley,et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication , 1987, Science.
[279] S. Loewe,et al. Antagonisms and antagonists. , 1957, Pharmacological reviews.
[280] G Milano,et al. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines , 2001, British Journal of Cancer.
[281] William E Grizzle,et al. Adenovirus-mediated FLT1-targeted proapoptotic gene therapy of human prostate cancer. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[282] T. Chou,et al. Comparison of dose-effect relationships of carcinogens following low-dose chronic exposure and high-dose single injection: an analysis by the median-effect principle. , 1980, Carcinogenesis.
[283] S. T. Cowan,et al. The strategy of chemotherapy. , 1958 .
[284] Jack J. Fox,et al. Biochemical Effects of 2′-Fluoro-5-methyl-1-β-d-arabinofuranosyluracil and 2′-Fluoro-5-iodo-1-β-d-arabinofuranosylcytosine in Mouse Leukemic Cells Sensitive and Resistant to 1-β-d-Arabinofuranosylcytosine , 1982 .
[285] K Nakatsu,et al. Effect of 5-isosorbide mononitrate on isosorbide dinitrate-induced relaxation of rabbit aortic rings. , 1984, Canadian journal of physiology and pharmacology.
[286] Palmer Taylor,et al. Principles of Drug Action , 1990 .
[287] T. Chou,et al. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: A rationale for combination therapy with chemotherapeutic agents , 1995, International journal of cancer.
[288] T. Chou,et al. Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. , 1976, Journal of theoretical biology.
[289] C. Gridelli,et al. Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro? , 2004, Anticancer research.
[290] John Leyden. Webb,et al. Enzyme and metabolic inhibitors , 1963 .
[291] G. Sager,et al. The effect of Mg2+, nucleotides and ATPase inhibitors on the uptake of [3H]-cGMP to inside-out vesicles from human erythrocytes. , 1999, Molecular membrane biology.
[292] T. Chou,et al. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: Curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[293] T. Chou,et al. A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. , 1977, The Journal of biological chemistry.
[294] Martin S. Hirsch,et al. Anti-Human Immunodeficiency Virus Interactions of SCH-C (SCH 351125), a CCR5 Antagonist, with Other Antiretroviral Agents In Vitro , 2002, Antimicrobial Agents and Chemotherapy.
[295] Alan S. Perelson,et al. Decay characteristics of HIV-1-infected compartments during combination therapy , 1997, Nature.
[296] Hermann Katinger,et al. Primary African HIV clade A and D isolates: effective cross-clade neutralization with a quadruple combination of human monoclonal antibodies raised against clade B. , 2003, AIDS research and human retroviruses.
[297] Alexey Rivkin,et al. Complex target-oriented total synthesis in the drug discovery process: the discovery of a highly promising family of second generation epothilones. , 2003, Journal of the American Chemical Society.
[298] M. Hirsch,et al. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. , 1996, Antiviral therapy.
[299] B. K. Chang,et al. Enhanced potency of daunorubicin against multidrug resistant subline KB-ChR-8-5-11 by a pulsed magnetic field. , 1997, Anticancer research.
[300] S. Loewe. The problem of synergism and antagonism of combined drugs. , 1953, Arzneimittel-Forschung.
[301] C E Leonard,et al. Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. , 1996, Cancer research.
[302] M. Hirsch,et al. Antagonism between human immunodeficiency virus type 1 protease inhibitors indinavir and saquinavir in vitro. , 1997, The Journal of infectious diseases.
[303] A. Söling,et al. Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells , 2003, Cancer Chemotherapy and Pharmacology.
[304] Xiuguo Zhang,et al. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity. , 2005, Bioorganic & medicinal chemistry.
[305] J B Smith,et al. Ca2+ influx via Na(+)-Ca2+ exchange in immortalized aortic myocytes. I. Dependence on [Na+]i and inhibition by external Na+. , 1992, The American journal of physiology.
[306] R. Martuza,et al. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. , 2006, Journal of the National Cancer Institute.
[307] D. Schoepp,et al. Metabotropic glutamate receptor modulation of cAMP accumulation in the neonatal rat hippocampus , 1993, Neuropharmacology.
[308] Christian Trepo,et al. Antiviral Activities of 2′-Fluorinated Arabinosyl—Pyrimidine Nucleosides , 1988 .
[309] G. Steel,et al. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. , 1979, International journal of radiation oncology, biology, physics.
[310] J R Maisin,et al. Effect of X-rays alone or combined with diethylnitrosamine on cancer induction in mouse liver. , 1987, International journal of radiation biology and related studies in physics, chemistry, and medicine.
[311] B J Berger,et al. Antimalarial activity of novel arylene bis(methylketone) compounds. , 1996, The Journal of infectious diseases.
[312] Laetitia Padovani,et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation , 2005, Molecular Cancer Therapeutics.
[313] R. H. Shanks,et al. Preclinical Evaluation of Gemcitabine Combination Regimens for Application in Acute Myeloid Leukemia , 2005, Clinical Cancer Research.
[314] T. Chou,et al. Models for Drug Development and Drug Resistance , 2007 .
[315] T. Chou,et al. Differential alteration of the anti-HIV-1 effect of phosphorothioate oligonucleotide S-dC28 by AZT, interferon-alpha, and dextran sulfate. , 1991, AIDS research and human retroviruses.
[316] Joseph Berkson,et al. The Application of the Logistic Function to Experimental Data. , 1928 .
[317] B D Kahan,et al. Effects of the pharmacokinetic interaction between orally administered sirolimus and cyclosporine on the synergistic prolongation of heart allograft survival in rats. , 1996, Transplantation.
[318] T. Chou,et al. 9-substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships. , 1995, Journal of medicinal chemistry.
[319] Taeyoung Yoon,et al. Enediyne Quinone Imines: Truncated, Biologically Active Dynemicin Congeners , 1995 .
[320] Lena Kanter,et al. Modulation of response to radiation of human lung cancer cells following insulin-like growth factor 1 receptor inactivation. , 2005, Cancer letters.
[321] E. Baba,et al. Synergistic interaction between oxaliplatin and SN-38 in human gastric cancer cell lines in vitro. , 2005, Oncology reports.
[322] B. Polsky,et al. Oltipraz, an inhibitor of human immunodeficiency virus type 1 replication. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[323] R. Stuart,et al. Role of glutathione in the in vitro synergism between 4-hydroperoxy-cyclophosphamide and cisplatin in leukemia cell lines. , 1991, Cancer research.
[324] G. Pasternak,et al. Opiate binding in calf thalamic membranes: a selective mu 1 binding assay. , 1988, Molecular pharmacology.
[325] Lin Ji,et al. Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells. , 2004, Journal of the National Cancer Institute.
[326] C. Crumpacker,et al. Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine. , 1984, Cancer research.
[327] Dale L. Boger,et al. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice , 2005, Cancer Chemotherapy and Pharmacology.
[328] S. Crooke,et al. Effect of anthracycline analogues on the appearance of newly synthesized total RNA and messenger RNA in the cytoplasm of erythroleukemia cells. , 1982, Molecular pharmacology.
[329] T C Noonan,et al. Effect of BI-L-239, A-64077 and MK-886 on leukotriene B4 synthesis by chopped guinea pig lung and on antigen-induced tracheal contraction in vitro. , 1992, Prostaglandins.
[330] J. Webster. Encyclopedia of Medical Devices and Instrumentation , 1988 .
[331] Sten Orrenius,et al. Buried alive: a novel approach to cancer treatment , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[332] Donghai Dai,et al. A potential synergistic anticancer effect of paclitaxel and amifostine on endometrial cancer. , 2005, Cancer research.
[333] Debabrata Banerjee,et al. Sequence-dependent synergistic cytotoxicity of ecteinascidin-743 and paclitaxel in human breast cancer cell lines in vitro and in vivo. , 2002, Cancer research.
[334] A. Rahier,et al. Cycloeucalenol-obtusifoliol isomerase. Structural requirements for transformation or binding of substrates and inhibitors. , 1989, European journal of biochemistry.
[335] T C Chou,et al. Rational approach to the clinical protocol design for drug combinations: a review. , 2000, Acta paediatrica Taiwanica = Taiwan er ke yi xue hui za zhi.
[336] T. Yonetani,et al. STUDIES ON LIVER ALCOHOL HYDROGENASE COMPLEXES. 3. MULTIPLE INHIBITION KINETICS IN THE PRESENCE OF TWO COMPETITIVE INHIBITORS. , 1964, Archives of biochemistry and biophysics.
[337] N. Saijo,et al. Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells , 2004, Anti-cancer drugs.
[338] M. Grever,et al. Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance. , 2005, Blood.
[339] R. He,et al. Combinations of retinoic acid with either sodium butyrate, dimethyl sulfoxide, or hexamethylene bisacetamide synergistically induce differentiation of the human myeloid leukemia cell line HL60. , 1990, Cancer research.
[340] Xiuguo Zhang,et al. Therapeutic cure against human tumor xenografts in nude mice by a microtubule stabilization agent, fludelone, via parenteral or oral route. , 2005, Cancer research.
[341] J Sühnel,et al. Evaluation of synergism or antagonism for the combined action of antiviral agents. , 1990, Antiviral research.
[342] G. Pasternak,et al. Identification of a high‐affinity orphanin FQ/nociceptin(1–11) binding site in mouse brain , 1999, Synapse.
[343] Yves Pommier,et al. DNA interaction and topoisomerase II inhibition by the antitumor agent 3'-(9-acridinylamino)-5'-hydroxymethylaniline and derivatives , 1996 .
[344] D. Schoepp,et al. Inhibition of Excitatory Amino Acid‐Stimulated Phosphoinositide Hydrolysis in the Neonatal Rat Hippocampus by 2‐Amino‐3‐Phosphonopropionate , 1989, Journal of neurochemistry.
[345] B D Kahan,et al. Computerized quantitation of immunosuppressive synergy for clinical protocol design. , 1994, Transplantation proceedings.
[346] Z. Yuan,et al. Active-site directed irreversible inhibition of diamine oxidase by a homologous series of aziridinylalkylamines. , 1992, Biochemical pharmacology.
[347] M. Niu,et al. Nevirapine, Zidovudine, and Didanosine Compared with Zidovudine and Didanosine in Patients with HIV-1 Infection , 1996, Annals of Internal Medicine.
[348] D R Burton,et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. , 1997, AIDS research and human retroviruses.
[349] C Ramel,et al. Deployment of short-term assays for the detection of carcinogens; genetic and molecular considerations. , 1986, Mutation research.
[350] H R Figulla,et al. Cultured human myocardial fibroblasts of pediatric origin: natural human interferon-alpha is more effective than recombinant interferon-alpha 2a in carrier-state coxsackievirus B3 replication. , 1995, Journal of molecular and cellular cardiology.
[351] R F Schinazi,et al. In-vitro activities of paromomycin and lasalocid evaluated in combination against Cryptosporidium parvum. , 1998, The Journal of antimicrobial chemotherapy.
[352] B D Kahan,et al. Synergistic interaction of 3 M KCl-extracted donor antigens (e-HAg) with cyclosporine or cyclosporine/sirolimus for prolongation of rat heart allograft survival. , 1995, Transplant immunology.
[353] C. Czajkowski,et al. Molecular dissection of benzodiazepine binding and allosteric coupling using chimeric gamma-aminobutyric acidA receptor subunits. , 1998, Molecular pharmacology.
[354] T. Chou,et al. Synergistic neutralization of HIV-1 by human monoclonal antibodies against the V3 loop and the CD4-binding site of gp120. , 1992, AIDS research and human retroviruses.
[355] Michele Caraglia,et al. Synergistic Antitumor Activity of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib and IFN-α in Head and Neck Cancer Cells In vitro and In vivo , 2006, Clinical Cancer Research.
[356] G. Konecny,et al. Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpression. , 2004, Oncology.
[357] D. Schoepp,et al. Cloning and expression of a human metabotropic glutamate receptor 1 alpha: enhanced coupling on co-transfection with a glutamate transporter. , 1995, Molecular pharmacology.
[358] M. Berenbaum. What is synergy? , 1989, Pharmacological reviews.
[359] M. Prichard,et al. A three-dimensional model to analyze drug-drug interactions. , 1990, Antiviral research.
[360] T. Chou,et al. Schedule-dependent synergism of taxol or taxotere with edatrexate against human breast cancer cells in vitro , 1995, Cancer Chemotherapy and Pharmacology.
[361] T. Chou,et al. Synergistic Inhibition of Epstein-Barr Virus: Transformation of B Lymphocytes by α and γ Interferon and by 3′-Azido-3′-Deoxythymidine , 1989 .
[362] R. Plackett,et al. Statistical aspects of the independent joint action of poisons, particularly insecticides; the toxicity of a mixture of poisons. , 2008, The Annals of applied biology.
[363] B D Kahan,et al. The Synergistic Effects Of Cyclosporine, Sirolimus, And Brequinar On Heart Allograft Survival In Mice , 1995, Transplantation.
[364] W. N. Sullivan,et al. Toxicity of rotenone and Pyretherins, Alone and in Combination , 1936 .
[365] Paul Talalay,et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[366] I. Todd,et al. Pharmacological Basis of Cancer Chemotherapy , 1976, British Journal of Cancer.
[367] T. A. Connors,et al. New Avenues in Developmental Cancer Chemotherapy , 1987 .
[368] T. Reader,et al. Dopamine D2 receptors labeled with [3H]raclopride in rat and rabbit brains. Equilibrium binding, kinetics, distribution and selectivity. , 1989, The Journal of pharmacology and experimental therapeutics.
[369] M. Shimkin,et al. Quantitative Analysis of Dose-Response Data Obtained With Three Carcinogenic Hydrocarbons in Strain C3H Male Mice , 1943 .
[370] P. Charlton,et al. Preclinical anti-tumor activity of XR5944 in combination with carboplatin or doxorubicin in non-small-cell lung carcinoma , 2005, Anti-cancer drugs.
[371] S H Snyder,et al. Heterogeneity of adenosine A1 receptor binding in brain tissue. , 1982, Molecular pharmacology.
[372] S S Ko,et al. Substrate-based inhibitors of lanosterol 14 alpha-methyl demethylase: I. Assessment of inhibitor structure-activity relationship and cholesterol biosynthesis inhibition properties. , 1995, Biochemistry.
[373] M C Berenbaum,et al. Synergy, additivism and antagonism in immunosuppression. A critical review. , 1977, Clinical and experimental immunology.
[374] Hiroshi Yasui,et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.
[375] C B Shields,et al. The rat hippocampal slice preparation as an in vitro model of ischemia. , 1988, Stroke.
[376] T C Chou,et al. Metabolic competition studies of 2'-fluoro-5-iodo-1-beta-d-arabinofuranosylcytosine in vero cells and herpes simplex type 1-infected vero cells. , 1984, Molecular pharmacology.
[377] B. Berger,et al. Studies on the mechanism of antimalarial action of a novel arylene bis(methylketone). , 1997, Biochemical pharmacology.
[378] E. Baba,et al. In vitro schedule-dependent interaction between paclitaxel and oxaliplatin in human cancer cell lines , 2005, Cancer Chemotherapy and Pharmacology.
[379] John W. Ferkany,et al. Receptor Binding , 2005 .
[380] T. Chou,et al. Characteristics of the combination paclitaxel plus doxorubicin in breast cancer cell lines analyzed with the ATP-Cell Viability Assay , 1993, Breast Cancer Research and Treatment.
[381] B D Kahan,et al. Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection , 1997, Clinical and experimental immunology.
[382] X. Breakefield,et al. Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies. , 1998, Journal of the National Cancer Institute.
[383] Tarik Tihan,et al. Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells , 2004, Cancer Chemotherapy and Pharmacology.
[384] Ting-Chao Chou,et al. Design, experimentation and computerized automated data analysis of synergistic drug combinations against xenograft tumors by Taxotere and T900607 , 2005 .
[385] T. Reader,et al. Alpha-adrenoceptors and monoamine contents in the cerebral cortex of the rodent Jaculus orientalis: Effects of acute cold exposure , 1986, Pharmacology Biochemistry and Behavior.
[386] Sandra Van Schaeybroeck,et al. Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy , 2005, Clinical Cancer Research.
[387] D. Bylund,et al. Alpha-2A and alpha-2B adrenergic receptor subtypes: antagonist binding in tissues and cell lines containing only one subtype. , 1988, The Journal of pharmacology and experimental therapeutics.
[388] W. Plunkett,et al. Selective action of 2',3'-didehydro-2',3'-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. , 1992, The Journal of biological chemistry.
[389] D. Schoepp,et al. Inhibition of Cyclic AMP Formation by a Selective Metabotropic Glutamate Receptor Agonist , 1992, Journal of neurochemistry.
[390] D Rodbard,et al. An exact correction to the "Cheng-Prusoff" correction. , 1988, Journal of receptor research.
[391] G. Hitchings,et al. Antagonists of nucleic acid derivatives. VIII. Synergism in combinations of biochemically related antimetabolites. , 1954, The Journal of biological chemistry.
[392] K. Savin,et al. Desoxyepothilone B is curative against human tumor xenografts that are refractory to paclitaxel. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[393] H A Dewar,et al. Neuropeptide Y and platelet aggregation by adrenaline. , 1989, Life sciences.
[394] Chris Gennings,et al. A Statistical Approach to the Construction and Analysis of Isobolograms , 1988 .
[395] J. Bertino,et al. Carboxypeptidase G2 enhances trimetrexate cytotoxicity in CCRF-CEM cell lines sensitive and resistant to methotrexate. , 1989, Advances in enzyme regulation.
[396] T. Chou,et al. The proliferative response of low‐density human cell cultures to tumor promoters and its relevance to carcinogenic mechanisms in vitro , 1984, International journal of cancer.
[397] G. Pasternak,et al. Sigma binding in a human neuroblastoma cell line. , 1996, Neurochemical research.